Glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists, such as exendin-4, have been used in the treatment of type 2 diabetes; they increase glucose-dependent insulin secretion, regulate gastric emptying and reduce food intake and body weight [1]. Here, GLP1R is linked to type 2 diabetes mellitus.